{"body":"<p>PrEP is the use of ARV drugs by HIV-negative individuals to reduce the acquisition of HIV infection. Based on evidence from randomized trials, open-label extension studies and demonstration projects, WHO recommended daily oral PrEP containing tenofovir in 2015 as an additional prevention choice for people at substantial risk of HIV infection. In 2019, WHO updated this recommendation to include an additional dosing regimen, called event-driven PrEP, for cisgender men who have sex with men.<\/p>&#13;\n&#13;\n<p>In 2021, WHO released a conditional recommendation that the dapivirine vaginal ring may be offered as an additional prevention choice for women\u2074 at substantial risk of HIV infection as part of combination prevention approaches <em>(12). <\/em> As evidence for other PrEP products, including long-acting formulations, becomes available, WHO may make new or updated recommendations for PrEP.<\/p>&#13;\n&#13;\n<div class=\"footer\">&#13;\n<p>\u00b3 WHO defines key populations as men who have sex with men, people in prisons and other closed settings, people who inject drugs, sex workers and transgender people.<\/p>&#13;\n&#13;\n<div class=\"footer\">\u2074 For the recommendation on the dapivirine vaginal ring, the term women applies to cisgender women, meaning women assigned female at birth. There is no research at this time to support the dapivirine vaginal ring for other populations.<\/div>&#13;\n<\/div>&#13;\n","title":"3.2 Pre-exposure prophylaxis for preventing the acquisition of HIV","nid":508,"vid":2726,"created":1631546270,"changed":1632907167,"field_content_type":{"tid":2,"name":"Content-Menulist","class":"content-menulist"}}